Ann: Clinical report on phenoxodiol at ASCO , page-4

IMO ... the S2 trial announcement shows that Yale can't figure out how PXD works on Prostate cancer yet. I don't know what the normal expected progression for cancer was within the sample groups, but to me, the significant statement was ... Conclusions: In this small population, phenoxodiol showed modest activity with a third of the patients demonstrating stable disease. Larger studies evaluating the relationship between IFN- and MCP-1 levels and disease progression are warranted."

Therefore Yale are confident enough to want to further evaluate the mechanism that appears to be triggered by PXD.

Which is good IMO.

Thing is ... we all know PXD won't show up as a silver bullet for late stage monotherapy cancer cure (Its either an early stage or combo treatment option it would seem) ... which is why the Ovature trial will lead the way to deciding what happens next and Yale can carry on with their protein PXD research or the same research can be contracted through someone like the Malaghan Institute, or PXD combo treatment trials are run by MSHL once Ovature results are known - or all or none of these depending on Ovature analysis.

Personally I'm still keen on Yale doing more research and just imagine the interest in their research if Ovature data starts to surprise to the upside.

We'll be taking PXD like asprin in years to come!

Regards